Chronic Myeloproliferative Disorders Terminated Phase 2 Trials for Sirolimus (DB00877)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01116232Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationSupportive Care